We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Molecular Blood Test Developed for Kidney Cancer

By LabMedica International staff writers
Posted on 29 Aug 2017
Print article
Image: An example of a TaqMan Low Density Array card; each well contains a specific miRNA forward primer, a specific miRNA TaqMan probe, and a reverse \"tail\" primer (Photo courtesy of Dana-Farber Cancer Institute).
Image: An example of a TaqMan Low Density Array card; each well contains a specific miRNA forward primer, a specific miRNA TaqMan probe, and a reverse \"tail\" primer (Photo courtesy of Dana-Farber Cancer Institute).
Kidney cancer is usually caught because of the symptoms a patient develops, but it is also possible for kidney cancer to be asymptomatic, with tumors growing quite large before causing pain or other noticeable problems.

The mechanisms involved in renal cell carcinoma (RCC) development and progression remain unclear, and new biomarkers are needed in routine practice to improve the diagnostic and/or prognostic accuracy. A blood test for kidney cancer, which is under development, could improve screening for this disease and help ensure that asymptomatic patients are diagnosed while their cancer is still treatable.

A team of scientists at the Jinling Hospital (Nanjing, China) measured the concentrations of 754 different microRNAs (miRNA) in blood samples from 33 patients with the most common type of kidney cancer (renal cell carcinoma) and 33 healthy individuals. An initial microarray survey of 754 miRNAs was firstly performed using the TaqMan Low Density Array followed by a hydrolysis probe-based quantitative reverse transcription polymerase chain reaction (RT-qPCR) validation from serum samples to identify significantly dysregulated miRNAs in RCC. The expression levels of miR-651 and miR-708 in 17 paired tumor tissues were also examined. Furthermore, in vitro tests including CCK8 proliferation, transwell and wound healing assays were conducted to explore the potential functions of miR-651 and miR-708 in RCC. Luciferase reporter assays combined with Western blotting were employed to validate the target genes.

The team found that the serum levels of four miRNAs were verified to be significantly increased, whereas the levels of four miRNAs were markedly decreased in RCC patients compared with the non-cancer controls. Of these eight microRNAs, statistical analysis revealed that the two known as miR-651 and miR-708, which decreased in the kidney cancer patients, exhibited the largest areas under the curve (0.888 and 0.832, respectively). This means that a test for these microRNAs could diagnose renal cell carcinoma with relatively high accuracy. They also investigated the functions of miR-651 and miR-708 and found evidence suggesting they act as tumor suppressors. A therapeutic that increases levels of miR-651 and miR-708 could therefore potentially serve as a new treatment for renal cell carcinoma.

Chunni Zhang, PhD, the lead author of the study, said, “The mechanisms involved in renal cell carcinoma development and progression are unclear, and there is no standard serological biomarker to facilitate diagnosis in patients with this disease. Both miR-651 and miR-708 may potentially serve as novel biomarkers for renal cell carcinoma and may act as tumor suppressors. Our findings indicate that targeting miR-651 and miR-708 by a genetic approach may provide a novel strategy for the treatment of renal cell carcinoma.” The study was presented at the 69th AACC Annual Scientific Meeting & Clinical Lab Expo, held July 30 to August 3, in San Diego, CA, USA.

Related Links:
Jinling Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.